LabMedica

Download Mobile App
Recent News Expo
Medica 2026
Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Single Molecule Array Predicts Survival After Prostatectomy

By LabMedica International staff writers
Posted on 03 Nov 2011
A fifth-generation digital immunoassay is a reliable predictor of five-year biochemical recurrence (BCR)-free survival following radical prostatectomy (RP).

The immunoassay uses Single Molecule Array (SiMoA) technology based upon the isolation of individual immunocomplexes on beads using standard enzyme linked immunosorbent assay (ELISA) reagents.

Scientists utilized frozen serum specimens, provided by the Langone Medical Center (New York University, NY, USA), and the Johns Hopkins University School of Medicine (Baltimore, MD, USA), from men who had undergone RP and who had no evidence of BCR using conventional Prostate Specific Antigen (PSA) measurement methods.

The Quanterix AccuPSA assay (Quanterix Corporation, Cambridge, MA, USA), was capable of accurately measuring PSA levels in all men following surgery. The Quanterix assay has an analytical sensitivity 1,000-fold lower than conventional ultra sensitive PSA assays. AccuPSA nadir levels were significantly different between the non-BCR group whose mean was 2.27 pg/mL and the BCR group whose mean was 46.99 pg/mL. A Kaplan-Meir analysis demonstrated for the five years follow-up, 100% of men with AccuPSA nadir values of less than 3 pg/mL did not develop BCR, whereas 62.5% of men with values greater than 3 pg/mL developed BCR. The sensitivity, specificity, positive predictive value and negative predictive value of the AccuPSA test was 100%, 75%, 69% and 100% respectively.

Herbert Lepor, MD, a prostate cancer expert at NYU, said, "These results have important implications for the way prostatectomy patients will be managed in the future. Not only will physicians be able to reassure patients who are at low risk of recurrence following radical prostatectomy, but the identification of a reliable predictor of recurrence soon after surgery has important implications for the frequency of PSA testing and selection of candidates for adjuvant therapy. In addition to providing patients with peace of mind, implementation of this test could lead to a reduction in healthcare costs.” The study was published online on October 12, 2011, in the British Journal of Urology International.


Related Links:
New York University Langone Medical Center
Johns Hopkins University School of Medicine
Quanterix Corporation




Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
New
Gold Member
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+

Latest Clinical Chem. News

Plasma Assay Measures Six Amyloid Beta Peptides for Alzheimer’s Treatment Research
03 Nov 2011  |   Clinical Chem.

Blood Biomarker Model May Help Estimate Five- and 10-Year Cognitive Impairment Risk
03 Nov 2011  |   Clinical Chem.

FDA Authorization Adds Gabapentin Testing to Roche Mass Spectrometry Solution
03 Nov 2011  |   Clinical Chem.